RYBREVANT® (amivantamab) plus chemotherapy shows positive overall survival trend ...
Updated MARIPOSA-2 study results show amivantamab plus chemotherapy significantly improves post-progression outcomes and overall survival in previously treated NSCLC patients with EGFR exon 19 deletions or L858R mutations, compared to chemotherapy alone.
Highlighted Terms
Janssen Biotech, Inc.Janssen-Cilag, S.A.amivantamabnon-small cell lung cancerEuropean CommissionEuropean Society of Medical OncologyRoyal Marsden HospitalYuhan CorporationJanssen Research & Development, LLCInstitute of Cancer ResearchEuropean Medicines AgencyJohnson & JohnsonNCT04988295chemotherapyJanssen-Cilag International NV
Related News
RYBREVANT® (amivantamab) plus chemotherapy shows positive overall survival trend ...
Updated MARIPOSA-2 study results show amivantamab plus chemotherapy significantly improves post-progression outcomes and overall survival in previously treated NSCLC patients with EGFR exon 19 deletions or L858R mutations, compared to chemotherapy alone.